These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 35731718)

  • 1. Activity of cefiderocol and synergy of novel β-lactam-β-lactamase inhibitor-based combinations against metallo-β-lactamase-producing gram-negative bacilli: insights from a two-year study (2019-2020).
    Boattini M; Comini S; Bianco G; Iannaccone M; Casale R; Cavallo R; Costa C
    J Chemother; 2023 May; 35(3):198-204. PubMed ID: 35731718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era.
    Bianco G; Boattini M; Comini S; Casale R; Iannaccone M; Cavallo R; Costa C
    Eur J Clin Microbiol Infect Dis; 2022 Apr; 41(4):573-580. PubMed ID: 35061145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions.
    Blanco-Martín T; Alonso-García I; González-Pinto L; Outeda-García M; Guijarro-Sánchez P; López-Hernández I; Pérez-Vázquez M; Aracil B; López-Cerero L; Fraile-Ribot P; Oliver A; Vázquez-Ucha JC; Beceiro A; Bou G; Arca-Suárez J;
    Int J Antimicrob Agents; 2024 May; 63(5):107150. PubMed ID: 38513748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of aztreonam-avibactam against Enterobacterales resistant to recently approved beta-lactamase inhibitor combinations collected in Europe, Latin America, and the Asia-Pacific Region (2020-2022).
    Sader HS; Carvalhaes CG; Kimbrough JH; Mendes RE; Castanheira M
    Int J Antimicrob Agents; 2024 Apr; 63(4):107113. PubMed ID: 38354826
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Huang YS; Chen PY; Chou PC; Wang JT
    Microbiol Spectr; 2023 Jun; 11(3):e0056923. PubMed ID: 37154758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam.
    Kang MS; Baek JY; Ko J-H; Cho SY; Lee KY; Lee YH; Yang J; Kim TY; Huh HJ; Lee NY; Huh K; Kang C-I; Chung DR; Peck KR
    Microbiol Spectr; 2024 Jun; 12(6):e0034424. PubMed ID: 38687076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases.
    Le Terrier C; Nordmann P; Poirel L
    J Antimicrob Chemother; 2022 Dec; 78(1):101-107. PubMed ID: 36308322
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Santerre Henriksen A; Jeannot K; Oliver A; Perry JD; Pletz MW; Stefani S; Morrissey I; Longshaw C;
    Microbiol Spectr; 2024 Apr; 12(4):e0383623. PubMed ID: 38483164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Minor Carbapenemases on Susceptibility to Novel β-Lactam/β-Lactamase Inhibitor Combinations and Cefiderocol in
    Sadek M; Bosch Duran J; Poirel L; Nordmann P
    Antimicrob Agents Chemother; 2023 May; 67(5):e0007823. PubMed ID: 37039645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales.
    Blanco-Martín T; López-Hernández I; Aracil B; González-Pinto L; Aja-Macaya P; Alonso-García I; Rodríguez-Pallares S; Sánchez-Peña L; Outeda-García M; Pérez-Vázquez M; Vázquez-Ucha JC; Beceiro A; Pascual Á; Bou G; López-Cerero L; Oteo-Iglesias J; Arca-Suárez J;
    Antimicrob Agents Chemother; 2024 Nov; 68(11):e0092424. PubMed ID: 39382274
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Wise MG; Karlowsky JA; Hackel MA; Takemura M; Yamano Y; Echols R; Sahm DF
    Microb Drug Resist; 2023 Aug; 29(8):360-370. PubMed ID: 37253158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of chromosomally encoded resistance mechanisms and transferable β-lactamases on the activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa.
    González-Pinto L; Alonso-García I; Blanco-Martín T; Camacho-Zamora P; Fraile-Ribot PA; Outeda-García M; Lasarte-Monterrubio C; Guijarro-Sánchez P; Maceiras R; Moya B; Juan C; Vázquez-Ucha JC; Beceiro A; Oliver A; Bou G; Arca-Suárez J
    J Antimicrob Chemother; 2024 Oct; 79(10):2591-2597. PubMed ID: 39073766
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Santerre Henriksen A; Arena F; Attwood M; Canton R; Gatermann S; Naas T; Morrissey I; Longshaw C;
    Microbiol Spectr; 2024 Jun; 12(8):e0418123. PubMed ID: 38904361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?
    Le Terrier C; Freire S; Nordmann P; Poirel L
    Eur J Clin Microbiol Infect Dis; 2024 Feb; 43(2):339-354. PubMed ID: 38095831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vitro Susceptibility of Aztreonam-Vaborbactam, Aztreonam-Relebactam and Aztreonam-Avibactam Associations against Metallo-β-Lactamase-Producing Gram-Negative Bacteria.
    Emeraud C; Bernabeu S; Dortet L
    Antibiotics (Basel); 2023 Sep; 12(10):. PubMed ID: 37887194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates.
    Meletiadis J; Paranos P; Georgiou PC; Vourli S; Antonopoulou S; Michelaki A; Vagiakou E; Pournaras S
    Int J Antimicrob Agents; 2021 Nov; 58(5):106440. PubMed ID: 34551356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of aztreonam in combination with ceftazidime-avibactam against serine- and metallo-β-lactamase-producing Pseudomonas aeruginosa.
    Lee M; Abbey T; Biagi M; Wenzler E
    Diagn Microbiol Infect Dis; 2021 Jan; 99(1):115227. PubMed ID: 33086177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of aztreonam in combination with novel β-lactamase inhibitors against metallo-β-lactamase-producing Enterobacterales from Spain.
    Vázquez-Ucha JC; Alonso-Garcia I; Guijarro-Sánchez P; Lasarte-Monterrubio C; Álvarez-Fraga L; Cendón-Esteve A; Outeda M; Maceiras R; Peña-Escolano A; Martínez-Guitián M; Arca-Suárez J; Bou G; Beceiro A;
    Int J Antimicrob Agents; 2023 Apr; 61(4):106738. PubMed ID: 36736925
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Hernández-García M; García-Castillo M; Ruiz-Garbajosa P; Bou G; Siller-Ruiz M; Pitart C; Gracia-Ahufinger I; Mulet X; Pascual Á; Tormo N; Cantón R
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0216121. PubMed ID: 35007130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.